Summary: Aims: Testicular seminomas require accurate staging for effective management. Twenty per cent are metastatic at presentation, while 80% are clinical stage I, requiring only orchiectomy and surveillance. Tumour size, rete testis invasion, hilar soft tissue invasion and lymphovascular invasion have been shown to incur a higher risk of metastasis and recurrence in clinical stage I seminomas, with little congruence between studies. Methods and results: We reviewed 211 cases of testicular seminomas and recorded patient age, tumour size, lymphovascular invasion and rete testis, hilar soft tissue, epididymis, spermatic cord, tunica albuginea and tunica vaginalis involvement. A univariate and multivariate analysis was performed comparing clinical stage I to advanced clinical stage patients (stages II and III) in reference to these factors. We found that tumour size (P = 0.02), vascular invasion (P = 0.02) and invasion of rete testis stroma (P = 0.01), epididymis (P = 0.02), spermatic cord (P = 0.047) and hilar soft tissue (P = 0.04) were predictors of higher clinical stage at the univariate level. However, multivariate analysis showed that only tumour size and vascular invasion remained significant (P = 0.008 and 0.032, respectively). A tumour size of 4 cm was the cut-off size found to be significant. Conclusions: Tumour size and vascular invasion are the strongest predictors of higher clinical stage in testicular seminomas. Our univariate data suggest that rete testis and hilar soft tissue invasion relate to higher clinical stage. However, neither of these factors were found to be independent risk factors at multivariate analysis. Therefore, this study supports tumour upstaging based only upon size and vascular invasion.
Introduction
Testicular germ cell tumours are the most common solid organ malignancy in males aged 20-35 years, with pure testicular seminomas representing up to 60%. 1 Seminomas are highly treatable, with 80% of patients presenting at low-stage disease (clinical stage I) and managed with orchiectomy and imaging surveillance. 2 However, many large studies have now
shown that the relapse rate of clinical stage I seminoma treated by orchiectomy and surveillance alone is between 15% and 20%. Most of these cases recur within 12-18 months and many are theorised to have occult metastases at the time of presentation. 3 Therefore, identifying risk factors for metastatic disease (or advanced clinical stage) is important to understand which patients are at a higher risk of subclinical metastases at presentation and, therefore, recurrence. Previous studies have attempted to develop models for risk of recurrence in clinical stage I seminomas. The results of these studies have been inconsistent with tumour size as the only consistent predictor of increased recurrence but with difference in cut-off sizes. Other purported predictors, including lymphovascular invasion, rete testis invasion and hilar soft tissue invasion, have had variable support. [4] [5] [6] [7] [8] [9] Furthermore, regarding clinical features Kollmannsberger et al. failed to find a correlation between current IGCCG risk stratification and relapse in seminomas. Thus, further characterisation of risk factors for recurrence, such as degree of locally advanced disease at the time of diagnosis, is needed. 10 Therefore, we wished to undertake a comprehensive analysis of possible prognostic factors in seminomas and their relationship to metastasis at the time of presentation, particularly in light of recent changes to the pathological staging of testicular germ cell tumours in the American Joint Committee on Cancer staging manual (8th edition).
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Methods
We collected retrospectively 211 consecutive in-house cases (2000-2016) of pure testicular seminomas and reviewed the microscopic slides, pathology reports and clinical histories. The final cohort consisted of 170 cases, as clinical stage was not available in 41 cases. The microscopic slides were reviewed by three pathologists prior to the collection of clinical stage data. Patient age, tumour size, lymphovascular invasion (LVI) and rete testis, hilar soft tissue, epididymis, spermatic cord, tunica albuginea and tunica vaginalis involvement were recorded. Direct rete testis and epididymal invasion versus pagetoid spread was specifically recorded. Rete testis tumour invasion was defined as tumour cells in the stroma on both sides of a tubular channel or clear destruction of the testicular hilum (Figure 1) , and hilar soft tissue invasion was defined as tumour extension into the soft tissue beyond the rete testis at the same plane of section as the testis parenchyma ( Figure 1 ). Spermatic cord invasion was defined as tumour extending grossly beyond the hilum, with the base defined as the section just superior to the head of the epididymis. Lymphovascular invasion was defined as cohesive cells, adherent to the wall of the vessel, located preferably in a peritumoral or tunica albuginea location. Associated fibrin material further supports the presence of Clinical stage was assessed from medical records at the time of presentation. Abdominal and pelvis CT and chest X-ray were available for all 170 patients included in the cohort. Additional evidence of metastasis and serum tumour markers were also noted when determining the clinical stage. Cases were then subclassified as either clinical stage I (including IA, IB and IS stages) or advanced clinical stage (stage II and above).
Binary categorical variables (lymphovascular, rete testis, hilar soft tissue, epididymis, spermatic cord, tunica albuginea and tunica vaginalis invasion) were collected and frequency and proportions were recorded for clinical stage I and advanced clinical stage groups. Continuous variables (age and tumour size) were kept in whole years for age and rounded to the nearest 1 mm for tumour size. Means were calculated for both age and tumour size in the clinical stage I and advanced clinical stage groups. On gross report and slide review, only tumour size, vascular invasion, spermatic cord invasion and tunica vaginalis invasion could be evaluated in every case included. A number of cases did not have adequate sampling of the testicular hilum and epididymis due to the year range that was included in the cohort. Therefore, each incomplete category had frequencies counted and proportions were calculated based on the number of cases that were evaluable for that particular variable. Additionally, frequencies were calculated for the number of cases less than and greater than 2, 3 and 4 cm in both the clinical stage I and advanced clinical stage groups.
A univariate and multivariate analysis was performed comparing clinical stage I to higher clinical stage patients (stages II and III) in reference to these factors. Univariate analysis was performed using Fisher's exact test for binary variables and the two-sample t-test for continuous variables. Additionally, v 2 testing was used to evaluate tumour size data with the various cut-offs recorded (2, 3 and 4 cm). Logistical regression was performed for multivariate analysis with forward stepwise selection of variables. The odds ratio was calculated for all statistically significant variables at the multivariate level. The final logistical regression model was used to form a receiver operating curve to evaluate the performance of the statistically significant variables at predicting higher clinical stage. A P-value of < 0.05 was set as statistically significant for all tests. All statistics were performed using Excel and SAS programs (Microsoft Office 2016; SAS Institute 2013).
Results
C L I N I C A L F I N D I N G S
Of the 170 cases included in the cohort, 138 (81%) were clinical stage I and 32 (19%) were advanced clinical stage (stages II and III). The mean patient age was 37 years (range = 19-68 years) ( Table 1) .
Of the 170 cases, the mean tumour size was 4.2 cm (range = 0.4-11.5 cm). Lymphovascular invasion was demonstrated in 25 cases (15%), spermatic cord invasion in five (3%) and tunica vaginalis involvement in four (2%). Rete testis invasion was identified in 90 of 155 (58%) cases, whereas pagetoid spread was seen in 28 of 145 (19%). Invasion of hilar soft tissue occurred in 34 of 158 (22%), epididymis in nine of 162 (6%) [with pagetoid spread in one of 160 (< 1%)] and tunica albuginea in 48 of 148 cases (32%). None of the cases had revised diagnoses (all remained pure seminoma) or revised clinical staging on re-review of the pathological and clinical data. As pathological staging was irrelevant to the analysis of each binary and continuous variable individually, these data were unaffected by the AJCC 8th edition update to testicular cancer staging. All cases were unilateral, with 211 separately represented patients.
The clinical and pathological findings in clinical stage I cases versus those of advanced clinical stage are shown in Table 1 . On univariate analysis, tumour size, vascular invasion, spermatic cord invasion and epididymal invasion were significantly more common in cases of advanced clinical stage than in stage I disease (Table 1) . Additionally, on univariate analysis, age, rete testis invasion, rete testis pagetoid spread, hilar soft tissue invasion, epididymal pagetoid spread, tunica vaginalis involvement and tunica albuginea involvement were not significantly different between cases of clinical stage I and advanced clinical stage.
On multivariate analysis, only tumour size and vascular invasion were significant independent predictors of higher clinical stage (Table 2) . A logistical regression model was created using these two variables and is represented in a receiver operating curve with an area under the curve of 0.7 ( Figure 2) .
Additionally, the various cut-offs trialled for tumour size showed a significantly higher risk of metastatic disease only with use of the 4-cm cut-off (Table 3 ). There was no statistical difference in the rate of advanced clinical stage when using both 2-and 3-cm cut-offs.
Discussion
This study identified tumour size and vascular invasion as strong predictors of advanced clinical stage and thus metastases at presentation in pure testicular seminomas. Additionally, we found the most appropriate cut-off point for upstaging based on tumour size to be < 4 cm versus ≥ 4 cm, based on the increased likelihood of metastases in tumours ≥ 4 cm. This was not true of the smaller cut-off values of 2 and 3 cm, respectively. These findings differ from those described previously in non-seminomatous germ cell tumours in the lack of support for hilar soft tissue, epididymal invasion, and rete testis invasion as prognostic risk factors, as well as the recently revised AJCC staging of germ cell tumours, which includes hilar soft tissue and epididymal invasion and a cut-off size of 3 cm. 11, 13 Previous studies on risk factors for recurrence in pure seminomas have identified tumour size, vascular invasion, rete testis invasion and increased age as predictors of recurrence or metastasis at presentation. However, many studies have found different and conflicting factors as significant, with validation in different institutions proving to be difficult. The largest of these studies demonstrated tumour size and rete testis invasion to be significant risk factors for recurrence in clinical stage I seminomas. 9 However, this study utilised pooled data from four different centres and historical data from pre-existing pathology reports without re-review of historic slides, unlike our study. Furthermore, external validation of this study by Chung et al. 4 identified only tumour size to be an independent risk factor at multivariate analysis, which was additionally supported by Vogt et al., who found rete testis involvement not to be a significant risk factor in a combined seminoma and non-seminoma cohort. 4, 7 The significance of tumour size was reconfirmed in a follow-up study by Nayan et al., which described significant differences in relapse rates of seminomas based on tumour size. 14 Other studies have found lymphovascular invasion and age to be significant risk factors, but these findings have not been confirmed in other institutions. 5, 8 As lymphovascular invasion is a well-supported prognostic factor in non-seminomatous germ cell tumours, the recent ISUP publication on reporting and staging testicular germ cell tumours calls specifically for further studies to provide high-level evidence of lymphovascular invasion in pure seminomas. 10, 12 Thus, our study helps to fill this need by providing specifically clear evidence of multivariate significance of lymphovascular invasion in pure seminomas.
Unlike the recent study on non-seminomatous germ cell tumours by Yilmaz et al., 10 our study did not find hilar soft tissue invasion and rete testis invasion to be independent predictors of advanced clinical stage in pure seminomas. However, our study concurred with Yilmaz et al., that vascular invasion is an independent risk factor. This lack of congruence between support for these risk factors (in particular hilar soft tissue and rete testis invasion) in seminomas and non-seminomas could be due to the aggressive nature of non-seminomas in comparison to pure seminomas, and this fact is not addressed adequately by the current AJCC staging system which cites evidence for upstaging based on hilar soft tissue and epididymal invasion based on studies conducted on only non-seminomas. 11 Although our results did not support other histological and clinical criteria as independent risk factors for metastases besides tumour size and vascular invasion, there were limits to our study. As testicular germ cell tumours are fairly uncommon tumours, the number of cases available to study was low and impacted upon the power of the study. In particular, the number of cases with advanced clinical stage (n = 32) in cases of pure seminoma were limited. In comparison to studies of non-seminomas in which presentation at a higher clinical stage is more likely, a large cohort of advanced clinical stage patients is unavailable. Similarly, our ability to analyse the impact of factors associated with local growth (advanced pathological T-stage) was limited by few cases showing aggressive local invasion because of the relatively indolent tendencies of many seminomas. Hence, we found only five cases with spermatic cord invasion, one with epididymal pagetoid spread, nine with epididymal invasion and four with tunica vaginalis invasion. The remaining criteria evaluated had a larger number of positive cases (n ≥ 25). Additionally, our multivariate analysis was impacted by missing data. Of the criteria studied, only vascular invasion, tumour size, age and spermatic cord invasion were available in all cases, while a number of the other cases were missing one or more of the studied criteria (Table 1 ). This led to cases being eliminated from consideration in the logistical regression. Similarly, a number of the criteria examined demonstrated a great deal of overlap, for example rete testis and hilar soft tissue, which made proving independence difficult. Thus, hilar invasion may be more easily proven significant by grouping all hilar invasion (rete testis, hilar soft tissue and epididymis invasion) into one category in future studies. While this would not allow for elucidation of each factor individually, it would allow for clarification of the impact of hilar invasion in pure seminomas, which other studies have also struggled to validate. 4 Our study was limited additionally by the use of advanced clinical stage at presentation as a proxy for increased risk of relapse. The use of advanced clinical stage at diagnosis as an alternative to direct recurrence data as a prognostic indicator was performed in a cohort of non-seminomas by Yilmaz et al. previously, and this paper is regarded as strong evidence in the recent AJCC 8th edition update. 11, 13 Advanced stage disease was chosen additionally over relapse data due directly to the confounded nature of current relapse data because of differences in treatment among those with clinical stage I disease during the time-period tested. While there is much support for the use of surveillance in all these patients, the clinical scenario, including the degree of locally advanced disease, the likelihood of patient compliance and patient anxiety, influences the decision of whether to use adjuvant chemotherapy or radiation at the time of orchiectomy. 15 Additionally, our institution is a tertiary care centre that provides orchiectomy and care planning for a large surrounding area. Thus, a number of patients chose to undergo surveillance closer to home once their original care plan was in place, making these data currently unavailable to us.
Lastly, this project was limited by data collection from a single institution. Collaboration was attempted with outside institutions, but we found the completeness of outside data sets (i.e. not differentiating rete testis invasion from pagetoid spread or lack of hilar soft tissue invasion data) to be a recurring problem. Additionally, grossing protocols differed between institutions, and we found sampling of both hilar regions and spermatic cord to be drastically different over time and in different locations. By adhering to a single institution, we were able to review the slides adequately from all cases included and access clinical data necessary to confirm the clinical stage.
The results of this study underscore the importance of tumour size and lymphovascular invasion in the risk stratification of pure testicular seminomas. While tumour size has been added recently to the AJCC staging system for testicular germ cell tumours, the cut-off provided is 3 cm, which is not supported by our current study. Additionally, tumour size is only used to subclassify pathological staging of pT1 into pT1a and pT1b. Without other evidence of advanced disease, these cases will both be considered clinical stage IA, and therefore at very low risk for recurrence. We have identified tumour size ≥ 4 cm as a risk factor for metastases and, as such, given equal weight as lymphovascular invasion in pathological staging. Consequently, our study supports adding tumour size of ≥ 4 cm to future staging systems as pT2 in cases of pure seminomas, and we call for continued study to validate this further at other institutions or in larger data sets. Other large cohort studies have also demonstrated the importance of tumour size in seminomas, leaving this factor as the lone histological criterion that has been well supported by outside studies in seminomas, in particular. 4, 7, 9 In addition to this outside support, the AJCC system notes that there is minimal support for a specific size cut-off in the current literature.
11 While Chung et al. and Nayan et al. both showed significant increase in relapse using a cut-off of 3 cm, both Warde et al.'s study and Groll et al.'s comprehensive review support the use of a 4-cm tumour cut-off size, and our study adds support to this value. 4, 9, 14, 15 In conclusion, vascular invasion and tumour size ≥ 4 cm are strong independent predictors of metastases in cases of pure testicular seminomas, with a fair predictive model using these two criteria alone (area under the curve = 0.7, Figure 2 ). Extratesticular extension in the hilum was not found to be a significant risk factor for metastases as has been shown for non-seminomatous germ cell tumours, due probably to the low rate of cases that present at this advanced stage in comparison to non-seminomatous germ cell tumours and the great deal of overlap between hilar soft tissue and rete testis invasion, making independence difficult to support by multivariate analysis.
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